CytomX Therapeutics (CTMX) Metrics: History & Chart

CytomX Therapeutics, Inc.(CTMX)

Biotechnology · South San Francisco, CA

$2.62+0.04 (+1.36%)

Delayed quote: Oct 6, 2026, 11:31 AM EDT

About CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.

South San Francisco, CA

69 employees

www.cytomx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Sean A. McCarthy

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-4.09%
30D Total Return	-30.46%
YTD Total Return	-39.44%
1Y Total Return	-21.82%
3Y Total Return	+109.75%
5Y Total Return	-47.25%
10Y Total Return	-83.75%
15Y Total Return	N/A
20Y Total Return	N/A

2026	-39.44%
2025	+313.59%
2024	-33.55%
2023	-3.13%
2022	-63.05%
2021	-33.89%
2020

CAGR TTM	-21.73%
CAGR 3Y	+28.00%
CAGR 5Y	-12.01%
CAGR 10Y	-16.62%
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	454.55
PE Ratio Avg TTM	7.33
PE Ratio Avg 3Y	6.61
Current VS TTM Avg	+6102.13%
Current VS 3Y Avg	+6776.93%
Current VS 5Y Avg	+6776.93%

All Metrics

CTMX Valuation Metrics

CTMX Stock Price Metrics

CTMX Dividend Metrics

CTMX Growth Rate Metrics

CTMX Discounted Cash Flow Metrics

CTMX Returns By Period

CTMX Yearly Returns

CTMX Average Annual Returns By Period (CAGR)

CTMX Revenue Metrics

CTMX PE Ratio Metrics

CTMX PS Ratio Metrics

CTMX PB Ratio Metrics

CTMX Price to Free Cash Flow Ratio Metrics

CTMX Debt to Equity Ratio Metrics

CTMX PEG Ratio Metrics

CTMX FCF Yield

CTMX Earnings Yield

CTMX EBITDA Yield

CTMX OCF Yield

CTMX EV/EBIT Ratio Metrics

CTMX EV/EBITDA Ratio Metrics

CTMX EV/Assets Ratio Metrics

CTMX EV/Sales Ratio Metrics

CTMX Current Ratio Metrics

CTMX Quick Ratio Metrics

CTMX ROIC Metrics

CTMX Return on Assets Metrics

CTMX Return on Equity Metrics

CTMX Net Profit Margin Metrics

CTMX Gross Profit Margin Metrics

CTMX Tax Rate Metrics

PS Ratio	30.86
PS Ratio Avg TTM	11.52
PS Ratio Avg 3Y	2.46
Current VS TTM Avg	+167.96%
Current VS 3Y Avg	+1156.25%
Current VS 5Y Avg	+1300.49%

PB Ratio	1.87
PB Ratio Avg TTM	4.83
PB Ratio Avg 3Y	5.15
Current VS TTM Avg	-61.32%
Current VS 3Y Avg	-63.66%
Current VS 5Y Avg	-54.49%

PFCF Ratio	15.47
PFCF Ratio Avg TTM	67.09
PFCF Ratio Avg 3Y	65.49
Current VS TTM Avg	-76.94%
Current VS 3Y Avg	-76.38%
Current VS 5Y Avg	+89.40%

Debt/Equity Ratio	0.02
Debt/Equity Ratio Avg TTM	0.04
Debt/Equity Ratio Avg 3Y	(0.13)
Current VS TTM Avg	-47.59%
Current VS 3Y Avg	+115.04%
Current VS 5Y Avg	+335.78%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	6.46%
FCF Yield Avg TTM	3.48%
FCF Yield Avg 3Y	3.48%
Current VS TTM Avg	+85.44%
Current VS 3Y Avg	+85.44%
Current VS 5Y Avg	-52.43%

Earnings Yield	0.22%
Earnings Yield Avg TTM	14.34%
Earnings Yield Avg 3Y	13.65%
Current VS TTM Avg	-98.47%
Current VS 3Y Avg	-98.39%
Current VS 5Y Avg	-98.39%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	46.68
Ev/Ebit Ratio Avg TTM	14.25
Ev/Ebit Ratio Avg 3Y	10.41
Current VS TTM Avg	+227.50%
Current VS 3Y Avg	+348.30%
Current VS 5Y Avg	+348.30%

Ev/Ebitda Ratio	44.25
Ev/Ebitda Ratio Avg TTM	13.55
Ev/Ebitda Ratio Avg 3Y	8.69
Current VS TTM Avg	+226.67%
Current VS 3Y Avg	+409.18%
Current VS 5Y Avg	+409.18%

Ev/Assets Ratio	1.45
Ev/Assets Ratio Avg TTM	3.28
Ev/Assets Ratio Avg 3Y	0.98
Current VS TTM Avg	-55.80%
Current VS 3Y Avg	+48.60%
Current VS 5Y Avg	+109.20%

Ev/Sales Ratio	30.23
Ev/Sales Ratio Avg TTM	11.13
Ev/Sales Ratio Avg 3Y	2.29
Current VS TTM Avg	+171.71%
Current VS 3Y Avg	+1219.67%
Current VS 5Y Avg	+2216.27%

Current Ratio	9.36
Current Ratio Avg TTM	6.13
Current Ratio Avg 3Y	1.91
Current VS TTM Avg	+52.66%
Current VS 3Y Avg	+391.05%
Current VS 5Y Avg	+342.12%

Quick Ratio	9.36
Quick Ratio Avg TTM	6.13
Quick Ratio Avg 3Y	1.91
Current VS TTM Avg	+52.66%
Current VS 3Y Avg	+391.05%
Current VS 5Y Avg	+342.12%

ROIC	(25.42%)
ROIC Avg 3Y	13.89%
ROIC Avg 5Y	(14.05%)
Current VS 3Y Avg	-282.99%
Current VS 5Y Avg	-80.95%
Current VS 10Y Avg	-3.98%

ROA	(20.89%)
ROA Avg TTM	(7.41%)
ROA Avg 3Y	(1.06%)
Current VS TTM Avg	-181.77%
Current VS 3Y Avg	-1878.57%
Current VS 5Y Avg	-358.09%

ROE	(26.37%)
ROE Avg TTM	0.74%
ROE Avg 3Y	28.30%
Current VS TTM Avg	-3653.91%
Current VS 3Y Avg	-193.18%
Current VS 5Y Avg	+60.10%

Net Profit Margin	(435.21%)
Net Profit Margin Avg TTM	(1174.65%)
Net Profit Margin Avg 3Y	(26.10%)
Current VS TTM Avg	+62.95%
Current VS 3Y Avg	-1567.52%
Current VS 5Y Avg	-427.26%

Gross Profit Margin	98.63%
Gross Pft Margin Avg TTM	99.51%
Gross Pft Margin Avg 3Y	100.00%
Current VS TTM Avg	-0.88%
Current VS 3Y Avg	-1.37%
Current VS 5Y Avg	-0.91%

Tax Rate	0.26%
Tax Rate Avg 3Y	17.77%
Tax Rate Avg 5Y	17.77%
Current VS 3Y Avg	-98.52%
Current VS 5Y Avg	-98.52%
Current VS 10Y Avg	+100.45%